LAVA Therapeutics NV - Asset Resilience Ratio
LAVA Therapeutics NV (LVTX) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of LAVA Therapeutics NV for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how LAVA Therapeutics NV's Asset Resilience Ratio has changed over time. See LVTX book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down LAVA Therapeutics NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LVTX market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: LAVA Therapeutics NV maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
LAVA Therapeutics NV Industry Peers by Asset Resilience Ratio
Compare LAVA Therapeutics NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for LAVA Therapeutics NV (2019–2024)
The table below shows the annual Asset Resilience Ratio data for LAVA Therapeutics NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 51.42% | $41.56 Million | $80.83 Million | +0.94pp |
| 2023-12-31 | 50.48% | $51.34 Million | $101.71 Million | +27.79pp |
| 2022-12-31 | 22.68% | $32.53 Million | $143.43 Million | -7.72pp |
| 2021-12-31 | 30.40% | $42.33 Million | $139.25 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $20.49 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $8.80 Million | -- |
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more